Sitemap
- Home
- Rare Blood Disorders
- Other topics
- Vaccines and Immunization
- Products
- Thyrogen® (thyrotropin alfa) for injection
- Avalide® (irbesartan-hydrochlorothiazide)
- Cerdelga® (eliglustat) capsules
- Sarclisa® (isatuximab-irfc) injection for intravenous use
- Ambien® (zolpidem tartrate) tablets
- Lantus® (insulin glargine injection) 100 Units/mL
- LEMTRADA® (alemtuzumab)
- Kevzara® (sarilumab) injection
- Rifadin® IV (rifampin for injection, USP)
- Ferrlecit® (sodium ferric gluconate complex in sucrose injection)
- Plavix® (clopidogrel bisulfate)
- JEVTANA® (cabazitaxel) injection
- JEVTANA® (cabazitaxel) injection: PROSELICA Trial - Efficacy & Safety Overview
- The CARD Trial Was the First Comparative, Prospective, Phase 4 Trial Evaluating JEVTANA® (cabazitaxel) injection vs Abiraterone or Enzalutamide1,2
- Understanding Mechanisms of Progression For Prostate Cancer
- JEVTANA® (cabazitaxel) injection Preparation & Administration1
- DURATION OF THERAPY
- JEVTANA® (cabazitaxel) injection Dosing and Dose Modifications1
- JEVTANA® (cabazitaxel) injection Is a Microtubule Inhibitor1,2
- PROSELICA Results Established JEVTANA® (cabazitaxel) injection 20 mg/m2 as the Recommended Dose1,2
- JEVTANA® (cabazitaxel) injection: CARD Trial - Efficacy & Safety Overview
- JEVTANA® (cabazitaxel) injection Is a National Comprehensive Cancer Network® (NCCN® ) Designated Category 1 Preferred Regimen following Docetaxel and Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).1
- TROPIC Results Validated JEVTANA® (cabazitaxel) injection as a 2nd-Line Treatment After Docetaxel in a Pivotal Phase 3 Trial vs Mitoxantrone1,2
- Pick a CARD
- The National Comprehensive Cancer Network® (NCCN® ) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Recommend mCRPC Patients Be Monitored Closely for Progression1,2
- JEVTANA® (cabazitaxel) injection: TROPIC Trial - Efficacy & Safety Overview
- Zaltrap® (ziv-aflibercept) Injection for intravenous infusion
- Qfitlia™ (fitusiran)
- Mechanism of action: how Qfitlia™ (fitusiran) helps restore hemostasis by lowering antithrombin for people with hemophilia1
Dosing for Qfitlia™ (fitusiran) is guided by antithrombin levels1
Safety information and adverse events on Qfitlia™ (fitusiran)
- INTERACTIVE DOSING TOOL FOR QFITLIA™
- Qfitlia™ (fitusiran) resources for healthcare professionals
Qfitlia™ (fitusiran) offers proven bleed protection with as few as 6 injections a year1
- YOUR REQUEST HAS BEEN SUBMITTED
- Qfitlia™ (fitusiran): illustrative patient profiles
Supporting your patients with HemAssist™
- Qfitlia™ (fitusiran): Contact a representative
Manage breakthrough bleeds with reduced doses and frequency of factor or BPA1*†
- Qfitlia™ (fitusiran): ATLAS clinical trial design
- Apidra® (insulin glulisine injection) 100 Units/mL
- Xenpozyme® (olipudase alfa-rpcp) for injection, 20mg
- ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
Your request has been submitted
- Clinical Cases
- Hemophilia A Case Study: Noah
- HCP resources
- Hemophilia A Case Study: Henry
- Contact a Representative
- Adult & Adolescent Study - Efficacy
- Pediatric Study - Trial Design
- About Hemophilia A
- Adult & Adolescent Study - Pharmacokinetics
- Dosing Calculator
- Hemophilia A Case Study: Aaron
- Surgical Data in Patients with Hemophilia A
- Resources for your patients
- Pediatric Study - Safety
- Adult & Adolescent Study - Safety
- Dosing regimen
- Hemophilia A Case Study: Peter
- Hemophilia A Case Study: Sean
- Pediatric Study - Results
- Hemophilia A Case Study: Otis
- Surgical Data in Patients with Hemophilia A
- Pediatric Study - Pharmacokinetics
- Mechanism of half-life extension (MOE)
- Adult & Adolescent Study - Trial Design
- Ambien CR® (zolpidem tartrate) extended-release tablets
- Cerezyme® (imiglucerase) for injection
- Lumizyme® (alglucosidase alfa)
- Renvela® (sevelamer carbonate)
- Tzield® (teplizumab-mzwv) injection 2mg/2mL
- Dupixent® (dupilumab) injection
- Flomax® (tamsulosin HCI) capsules
- Cablivi® (caplacizumab-yhdp)
- Caprelsa® (vandetanib) Tablets
- Elitek® (rasburicase) IV infusion
- Clolar® (clofarabine injection)
- Mozobil® (plerixafor) injection
- ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
- Aldurazyme® (laronidase)
- Synvisc-One® (hylan G-F 20)
- Toujeo® (insulin glargine injection) 300 Units/mL
- Amaryl® (glimepiride tablets)
- Hectorol® (doxercalciferol) injection
- Avapro® (irbesartan)
- Arava® Tablets (leflunomide)
- Aubagio® (teriflunomide)
- Priftin® (rifapentine) Tablets
- Synvisc® (hylan G-F 20)
- Fabrazyme® (agalsidase beta)
- Nexviazyme™ (avalglucosidase alfa-ngpt)
- multaq (dronedarone)
- Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)]
- Rezurock (belumosudil) tablets
- Renagel® Tablets (sevelamer hydrochloride) 800mg tablets
- Beyfortus® (nirsevimab-alip) injection
One Last Step
- Cost & Coverage
- Register Now!
- Request a representative
- Articles
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection Frequently Asked Questions
- Order Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection for Your Practice
- Dosing & Administration
Thank you for connecting with us!
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection Resources
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg information for OBGYNs
Sign Up for the Latest Updates
- Mechanism of action for Beyfortus® (nirsevimab-alip) 50mg and 100mg Injection
- About RSV
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection Efficacy and Safety Profile Overview
- The Beyfortus® (nirsevimab-alip) Expert Series
- ADMELOG® (insulin lispro injection) 100 Units/mL
- Lovenox® (enoxaparin sodium injection) - 2
- ENJAYMO® (sutimlimab-jome) injection for intravenous use
- HemAssist™
- Primaquine® (Primaquine Phosphate Tablets)
- Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
- ALPROLIX® offers effective hemostatic control for both major and minor surgeries1
- Demonstrated safety profile for ALPROLIX® for patients across all ages and settings1
- A decade of dedication: our unwavering commitment to you and your patients
- Your request has been submitted
- Many patients with hemophilia B may adjust their management approach over time to fit their needs1,2
- On-demand dosing with ALPROLIX® can be used to control your patients' bleeding episodes1
- Extravascular distribution
- The behavior of factor IX in the body is complex
- Fc Fusion allows ALPROLIX® to mirror the pathway followed by endogenous factor IX
- ALPROLIX® is the only factor IX to utilize half-life extension with Fc Fusion technology
- ALPROLIX® prophylaxis offers bleed and joint bleed protection1*
- ALPROLIX® prophylaxis has extended dosing vs SHLs that helps reduce the treatment burden1,2
- ALPROLIX® offers hemostatic control for both major and minor surgeries1
- ALPROLIX® has a decade of experience your patients can trust1
- Efficacy on-demand
- Bleed reduction observed in real-world SHL switches1
- Contact a Representative
- Soliqua® 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL
- Therapeutic Areas
- Sitemap
- Terms of Use
- Privacy Policy
- Cookie Policy
